Zibotentan plus dapagliflozin shows no HVPG reduction in compensated cirrhosis
Early trial shows zibotentan plus dapagliflozin trended toward lowering blood pressure in cirrhosis patients
This Phase II randomized placebo-controlled exploratory study in 28 patients with compensated cirrhosis found that zibotentan 2.5 mg plus da…
An early study found that a combination drug lowered blood pressure in patients with compensated cirrhosis, though it did not conclusively i…
Seladelpar shows improved composite endpoint and ALP reduction in PBC with compensated cirrhosis.
New Drug Helps Liver Disease Patients With Cirrhosis
A phase 3 RCT program (RESPONSE and ASSURE studies) in patients with primary biliary cholangitis and compensated cirrhosis found seladelpar …
A new drug lowers liver stress markers in patients with cirrhosis, offering hope where older medicines often failed to stop disease progress…